ArticleCirculation. Genomic and precision medicine2025
Dynamic Importance of Genomic and Clinical Risk for Coronary Artery Disease Over the Life Course.
Article in Circulation. Genomic and precision medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Use of a polygenic risk score to enhance early detection of coronary atherosclerosis.American journal of preventive cardiology · 2026Article
- Article
- Combining Genomics With Lipid and Inflammatory Biomarkers to Predict Coronary Artery Disease Risk: UK Biobank Study.Journal of the American College of Cardiology · 2026Article
- Reply to the correspondence regarding our original paper "Integration of polygenic risk score with measured blood pressure reveals hidden risks of cardiovascular disease mortality: A Japanese prospective cohort study".Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Polygenic risk scores enhance LDL cholesterol-based risk stratification for coronary artery disease.American journal of preventive cardiology · 2026Article
- TNFR Pathway-Related Proteins and Recurrent Coronary Artery Disease Events.JACC. Advances · 2026Article
- An integrated germline and somatic genomic model for coronary artery disease.Nature communications · 2026Article
- Economic modeling of polygenic risk prediction of coronary artery disease in childhood.NPJ cardiovascular health · 2026Article
- Review
- Risk prediction for cardiovascular related diseases using PRS and EHR in the Framingham Heart Study.PloS one · 2026Article
- Polygenic risks and cardiovascular treatment effects in severe mental illness.Psychiatric genetics · 2025Article
- ALADYNOULLI: A Bayesian approach to disease progression modeling for genomic discovery and clinical prediction.medRxiv : the preprint server for health sciences · 2025Article
- Breaking binary in cardiovascular disease risk prediction.NPJ cardiovascular health · 2025Review
- Polygenic Risk Scores in Human Disease.Clinical chemistry · 2025Review
- Polygenic Risk Is Associated With Long-Term Coronary Plaque Progression and High-Risk Plaque.JACC. Cardiovascular imaging · 2024Article
- Screening embryos for polygenic disease risk: a review of epidemiological, clinical, and ethical considerations.Human reproduction update · 2024Review
- Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2024Review
- Clinical applications of polygenic risk score for coronary artery disease through the life course.Atherosclerosis · 2023Review
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
backgroundEarlier identification of high coronary artery disease (CAD) risk individuals may enable more effective prevention strategies. However, existing 10-year risk frameworks are ineffective at earlier identification. We sought to understand how the variable importance of genomic and clinical factors across life stages may significantly improve lifelong CAD event prediction.
methodsA longitudinal study was performed using data from 2 cohort studies: the FOS (Framingham Offspring Study) with 3588 participants aged 19 to 57 years and the UKB (UK Biobank) with 327 837 participants aged 40 years to 70 years. A total of 134 765 and 3 831 734 person-time years were observed in FOS and UKB, respectively. Hazard ratios for CAD were calculated for polygenic risk score (PRS) and clinical risk factors at each age of enrollment. The relative importance of PRS and pooled cohort equations in predicting CAD events was also evaluated by age groups.
resultsThe importance of CAD PRS diminished over the life course, with a hazard ratio of 3.58 (95% CI, 1.39-9.19) at the age of 19 years in FOS and a hazard ratio of 1.51 (95% CI, 1.48-1.54) by the age of 70 years in UKB. Clinical risk factors exhibited similar age-dependent trends. PRS significantly outperformed pooled cohort equations in identifying subsequent CAD events in the 40- to 45-year age group, with 3.2-fold more appropriately identified events. Overall, adding PRS improved the area under the receiving operating curve of the pooled cohort equations by an average of +5.1% (95% CI, 4.9%-5.2%) across all age groups; among individuals <55 years, PRS augmented the area under the receiver operater curve (ROC) of the pooled cohort equations by 6.5% (95% CI, 5.5%-7.5%;
conclusionsGenomic and clinical risk factors for CAD display time-varying importance across the lifespan. The study underscores the added value of CAD PRS, particularly among individuals younger than 55 years, for enhancing early risk prediction and prevention strategies. All results are available at https://surbut.github.io/dynamicHRpaper/index.html.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.